01:15 , Jan 12, 2019 |  BioCentury  |  Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
19:24 , Dec 21, 2018 |  BC Week In Review  |  Financial News

New Rhein raises $47.7M towards debut fund

New Rhein Healthcare Investors raised on Dec. 19 $47.7 million toward its debut fund, a pooled fund that will focus on both therapeutics and medical devices. It has an additional $15 million commitment, which it...
00:21 , Dec 20, 2018 |  BC Extra  |  Financial News

New Rhein raises $47.7M towards debut fund

New Rhein Healthcare Investors raised $47.7 million toward its debut fund, a pooled fund that will focus on both therapeutics and medical devices. It has an additional $15 million commitment, which it will receive when...
02:00 , Nov 17, 2018 |  BioCentury  |  Emerging Company Profile

Sepset’s sepsis signature

Sepset Biosciences Inc.’s gene expression test detects an "endotoxin tolerance" signature that can diagnose sepsis as soon as patients appear in an emergency room, earlier than approved assays and thereby providing more time for antibiotics...
18:09 , May 11, 2018 |  BC Week In Review  |  Company News

Merck, J&J vaccines ready for Ebola outbreak

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced an Ebola virus outbreak in the...
23:04 , May 9, 2018 |  BC Extra  |  Politics & Policy

Merck, J&J vaccines ready for Ebola outbreak

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced Tuesday an Ebola virus outbreak in...
22:56 , Feb 22, 2018 |  BioCentury  |  Finance

Belgian Insights

Belgium has provided Europe with a host of pioneering biotechs, led by CEOs who have demonstrated resilience and stamina in the pursuit of homegrown innovation. The opening evening session on May 14 at Bio€quity Europe...
22:09 , Dec 1, 2017 |  BC Week In Review  |  Financial News

Biocartis raises EUR80M in private placement

On Nov. 28, diagnostic company Biocartis Group N.V. (Euronext:BCART) raised €80 million ($94.4 million) through the sale of 6.4 million new shares at €12.50 in a private placement underwritten by JPMorgan, Degroof Petercam, KBC Securities...
00:10 , Nov 29, 2017 |  BC Extra  |  Financial News

Biocartis raises €80M in private placement

Diagnostic company Biocartis Group N.V. (Euronext:BCART) raised €80 million ($94.4 million) through the sale of 6.4 million new shares at €12.50 in a private placement underwritten by JPMorgan, Degroof Petercam, KBC Securities and Kempen &...
18:55 , Oct 27, 2017 |  BC Week In Review  |  Company News

Genomic Health Licenses Biocartis' Idylla platform

Genomic Health Inc. (NASDAQ:GHDX) will develop an in vitro version of its Oncotype DX breast cancer assay using the Idylla molecular diagnostics platform from Biocartis Group N.V. (Euronext:BCART). Biocartis received $3.3 million up front and...